EP3941512A4 - Treatment of cancers using sephb4-hsa fusion proteins - Google Patents
Treatment of cancers using sephb4-hsa fusion proteins Download PDFInfo
- Publication number
- EP3941512A4 EP3941512A4 EP20772615.9A EP20772615A EP3941512A4 EP 3941512 A4 EP3941512 A4 EP 3941512A4 EP 20772615 A EP20772615 A EP 20772615A EP 3941512 A4 EP3941512 A4 EP 3941512A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- sephb4
- cancers
- treatment
- fusion proteins
- hsa fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819642P | 2019-03-17 | 2019-03-17 | |
US201962819725P | 2019-03-18 | 2019-03-18 | |
PCT/US2020/023215 WO2020190977A1 (en) | 2019-03-17 | 2020-03-17 | Treatment of cancers using sephb4-hsa fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3941512A1 EP3941512A1 (en) | 2022-01-26 |
EP3941512A4 true EP3941512A4 (en) | 2022-12-21 |
Family
ID=72520496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20772615.9A Pending EP3941512A4 (en) | 2019-03-17 | 2020-03-17 | Treatment of cancers using sephb4-hsa fusion proteins |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220249621A1 (en) |
EP (1) | EP3941512A4 (en) |
JP (1) | JP2022525223A (en) |
KR (1) | KR20220015375A (en) |
CN (1) | CN113939309A (en) |
AU (1) | AU2020241963A1 (en) |
CA (1) | CA3133437A1 (en) |
WO (1) | WO2020190977A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020221276A1 (en) * | 2019-02-13 | 2021-10-07 | Vasgene Therapeutics, Inc | EphB4-Ephrin B2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
US20230312732A1 (en) * | 2020-06-17 | 2023-10-05 | 4C Biomed Services Ltd. | Ephb2 antibody and use thereof in combination therapy |
JP2024511995A (en) * | 2021-03-18 | 2024-03-18 | クラスノペロフ,ヴァレリー | Use of sEphB4-HSA fusion protein as first-line therapy in cancer treatment |
KR20240053651A (en) * | 2021-09-07 | 2024-04-24 | 바스진 테라퓨틱스, 인크. | Cancer diagnosis method using ephrin B2 expression |
WO2023154948A1 (en) * | 2022-02-14 | 2023-08-17 | Vasgene Therapeutics Inc. | Ephrin type-b receptor 4 (ephb4) agents and production thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020168110A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2703136A1 (en) * | 2007-03-12 | 2008-09-18 | Vasgene Therapeutics, Inc. | Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer |
-
2020
- 2020-03-17 AU AU2020241963A patent/AU2020241963A1/en active Pending
- 2020-03-17 WO PCT/US2020/023215 patent/WO2020190977A1/en unknown
- 2020-03-17 CA CA3133437A patent/CA3133437A1/en active Pending
- 2020-03-17 US US17/439,926 patent/US20220249621A1/en active Pending
- 2020-03-17 EP EP20772615.9A patent/EP3941512A4/en active Pending
- 2020-03-17 CN CN202080036834.1A patent/CN113939309A/en active Pending
- 2020-03-17 KR KR1020217033333A patent/KR20220015375A/en unknown
- 2020-03-17 JP JP2021555607A patent/JP2022525223A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020168110A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
Non-Patent Citations (6)
Title |
---|
ANONYMOUS: "History of Changes for Study: NCT02717156, Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcino", 17 May 2018 (2018-05-17), pages 1 - 6, XP055978628, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT02717156?V_6=View#StudyPageTop> [retrieved on 20221107] * |
ANONYMOUS: "History of Changes for Study: NCT03049618, Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475", 30 March 2018 (2018-03-30), pages 1 - 6, XP055978614, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT03049618?V_3=View#StudyPageTop> [retrieved on 20221107] * |
BHATIA SHILPA ET AL: "Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers", CANCER RESEARCH, vol. 79, no. 10, 15 May 2019 (2019-05-15), 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas, pages 2722 - 2735, XP055979528, ISSN: 0008-5472, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article-pdf/79/10/2722/2604555/2722.pdf> DOI: 10.1158/0008-5472.CAN-18-3257 * |
LODOLA ALESSIO ET AL: "Targeting Eph/ephrin system in cancer therapy", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 142, 18 July 2017 (2017-07-18), pages 152 - 162, XP085264360, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2017.07.029 * |
REN LIU ET AL: "EphB4 as a therapeutic target in mesothelioma", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 13, no. 1, 30 May 2013 (2013-05-30), pages 269, XP021152101, ISSN: 1471-2407, DOI: 10.1186/1471-2407-13-269 * |
See also references of WO2020190977A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA3133437A1 (en) | 2020-09-24 |
KR20220015375A (en) | 2022-02-08 |
US20220249621A1 (en) | 2022-08-11 |
WO2020190977A1 (en) | 2020-09-24 |
JP2022525223A (en) | 2022-05-11 |
EP3941512A1 (en) | 2022-01-26 |
AU2020241963A1 (en) | 2021-11-04 |
CN113939309A (en) | 2022-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3941512A4 (en) | Treatment of cancers using sephb4-hsa fusion proteins | |
EP3880814A4 (en) | Fusion protein | |
EP3820887A4 (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
EP3743438A4 (en) | Cytokine fusion proteins | |
EP3880239A4 (en) | THERAPEUTIC SIRPalpha ANTIBODIES | |
EP3757218A4 (en) | Fusion protein | |
EP3663319A4 (en) | Preparation method for novel fusion protein and use of fusion protein for improving protein synthesis | |
EP3883580A4 (en) | Methods of treating cancers | |
EP3971214A4 (en) | Fusion protein for treatment of metabolic disease | |
EP3937964A4 (en) | Treatment of oncogene-driven cancers | |
EP3265477A4 (en) | Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases | |
EP4069288A4 (en) | Methods of treatment using ilt7 binding proteins | |
EP3678701A4 (en) | Therapeutic protein compositions and methods of making and using the same | |
EP3814385A4 (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
IL290660A (en) | Therapeutic fusion proteins | |
EP3980067A4 (en) | Antibody-interleukin fusion protein and methods of use | |
EP3998282A4 (en) | Novel fusion protein and use of same | |
EP3917943A4 (en) | Methods of protein purification | |
EP3708661A4 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
EP3891175A4 (en) | Modified proteins and associated methods of treatment | |
EP3650539A4 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
EP3893931A4 (en) | Methods of using anti-trem2 antibodies | |
EP3920956A4 (en) | Methods of using glycopolysialylated therapeutic proteins | |
EP3600429A4 (en) | Il-37 fusion protein and methods of making and using same | |
EP4013445A4 (en) | Therapeutic protein compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211011 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221117 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20221111BHEP Ipc: A61K 47/50 20170101ALI20221111BHEP Ipc: A61K 38/17 20060101ALI20221111BHEP Ipc: C07K 7/04 20060101ALI20221111BHEP Ipc: A61K 39/00 20060101AFI20221111BHEP |